Sun Pharma Q2 profit falls 36% as revenue rises 11.8%
In short
Sun Pharma reported a 36% drop in net profit for the quarter, even though revenue rose 11.8%. Growth came mainly from India and emerging markets, while U.S. formulation sales fell.
This matters because the company is still growing overall, but profit was weaker. The report does not say exactly how much of the profit drop came from exceptional items.
What the reporting says
Sun Pharmaceutical reported a 36% drop in net profit for Q2 even as consolidated revenue rose 11.8%, according to a publisher-supplied summary. The revenue increase was driven mainly by strong sales in India and emerging markets, especially domestic formulations, while U.S. formulation sales fell sharply. The company also said it made progress on integration planning for the Organon acquisition after regulatory approvals, but the exact profit hit from exceptional items was not stated.
Why it matters
Sun Pharmaceutical reported a 36% decline in net profit alongside an 11.8% rise in consolidated revenue. The summary says India and emerging markets, especially domestic formulations, supported sales, while U.S. formulation sales weakened. It also says the company advanced integration planning for the Organon acquisition after regulatory approvals. The reporting does not quantify the exceptional items or the near-term earnings impact.